The Early Drug Discovery Unit (EDDU) at the University of Barcelona has recently been awarded the prestigious TECNIO quality seal by the Government of Catalonia through ACCIÓ. This recognition identifies entities that develop and facilitate technology for companies, highlighting their capacity to transfer knowledge and technology to the productive sector.
EDDU is led by Dr. Carles Galdeano, a professor at the Faculty of Pharmacy and Food Sciences at the University of Barcelona. The group is also part of the Institute of Biomedicine of the University of Barcelona (IBUB), which reinforces its connection to excellence in biomedical research. EDDU focuses on early-stage drug discovery, concentrating on the development of new therapeutic molecules and the identification of innovative pharmacological targets.
The research team includes Dr. Jordi Juárez, Dr. Carmen Escolano, Dr. Diego Muñoz-Torrero, Dr. Santiago Vázquez, Dr. Andreea Larisa Turcu, and Dr. Salomé Llabrés. Their combined expertise spans medicinal chemistry, pharmacology, and computational drug design, contributing significantly to the group’s multidisciplinary approach.
Prior to obtaining the TECNIO accreditation, EDDU had been selected as a PRE-TECNIO group in the 2023/24 and 2024/25 calls for the intensification of transfer activities by the Vice-Rectorate for Entrepreneurship, Innovation and Transfer at the University of Barcelona. These calls aimed to encourage the creation or consolidation of transfer groups and prepare them for obtaining the TECNIO seal within a four-year period, a goal that EDDU has successfully achieved.
With this accreditation, EDDU consolidates its position as a key player in technology transfer in the field of biomedicine, reinforcing the commitment of the University of Barcelona and IBUB to applied research and collaboration with the business community.
FBG news source [+]
More information about EDDU Unit [+]
